Focus on Semaglutide 2.4 Mg/Week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Phase II and III clinical trials show that subcutaneous semaglutide 2.4 mg/week leads to significant improvements in hepatic steatosis, disease activity, resolution of metabolic dysfunction-associated steatohepatitis and reduction in liver fibrosis.